All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
FDA grants orphan drug designation to “universal, off the shelf” NK cell therapy product for the treatment of MM
On October 12, 2020, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to a “universal, off the shelf” NK cell therapy product (oNKord®) for the treatment of patients with multiple myeloma (MM).1
An off the shelf approach, ensuring large-scale production from a single manufacturing run, may represent a valid alternative to the traditional approach by addressing the unmet need of treating large cohorts of patients.2
This NK cell therapy product, manufactured from fresh umbilical cord blood stem cells,2 has already received FDA and European Medicines Agency (EMA) orphan drug designation for the treatment of acute myeloid leukemia (AML)1. Promising results were observed in the first-in-human study in elderly patients with AML who were not eligible for allogeneic stem cell transplantation.3 Therefore, an ongoing phase I-IIa, open-label, multicenter trial (EudraCT Number 2019-003686-17) is evaluating the safety and efficacy of this product in patients with AML who are in complete morphologic remission.1
A phase II trial for patients with MM is planned to start in 2021.
Read more about NK cell therapy for the treatment of MM, here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?